Anlotinib Combined with Etoposide as Maintenance Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

被引：0
|
作者：
Shen, B. [1 ]
Wu, Y. [2 ]
Shi, L. [1 ]
Feng, J. [1 ]
机构：
[1] Jiangsu Canc Hosp, Nanjing, Peoples R China
[2] Jiangsu Canc Hosp, Med Oncol, Nanjing, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Anlotinib; Etoposide; Extensive-stage small cell lung cancer;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P48.24
引用
收藏
页码：S509 / S510
页数：2
相关论文
共 50 条
  • [1] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): A single-arm, prospective phase II study
    Shen, B.
    Wu, Y.
    Shi, L.
    Feng, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1040 - S1040
  • [2] Anlotinib combined with etoposide as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): Updated results from a phase II trial.
    Shen, Bo
    Wu, Yuan
    Shi, Lin
    Pan, Banzhou
    Yang, Kaihua
    Wang, Qiong
    Zhao, Weiqing
    Han, Zhengxiang
    Wang, Lifeng
    Feng, Jifeng
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
    Gao, F.
    Zhao, Y.
    Li, X.
    Li, Y.
    Ma, T.
    Li, Q.
    Tang, X.
    Han, X.
    Yi, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S1069 - S1069
  • [4] The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
    Browne, C.
    Ayoube, T.
    Samarasinghe, N.
    Hussaini, K.
    Warner, A.
    Black, M.
    Palma, D. A.
    Raphael, J.
    Kuruvilla, M. S.
    Blanchette, P.
    ANNALS OF ONCOLOGY, 2023, 34 : S1065 - S1065
  • [5] Paraneoplastic acquired haemophilia A in extensive-stage small cell lung cancer (ES-SCLC) in the era of immunotherapy
    Pauls, Mehrnoosh
    Rydz, Natalia
    Nixon, Nancy A.
    Ezeife, Doreen
    BMJ CASE REPORTS, 2021, 14 (01)
  • [6] Patterns of Disease Progression after Carboplatin/Etoposide plus Atezolizumab in Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
    Higgins, K. A.
    Curran, W. J., Jr.
    Liu, S. V.
    Yu, W.
    Brockman, M.
    Johnson, A.
    Bara, I.
    Bradley, J. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2020, 108 (05): : 1398 - 1398
  • [7] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Kong, Tiandong
    Chen, Lu
    Zhao, Xiaoli
    Duan, Fangfang
    Zhou, Hanli
    Wang, Lei
    Liu, Danna
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (05) : 1095 - 1105
  • [8] Anlotinib plus etoposide and cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): a single-arm, phase II study
    Tiandong Kong
    Lu Chen
    Xiaoli Zhao
    Fangfang Duan
    Hanli Zhou
    Lei Wang
    Danna Liu
    Investigational New Drugs, 2022, 40 : 1095 - 1105
  • [9] COST OF IMMUNOTHERAPY TO TREAT EXTENSIVE STAGE SMALL CELL LUNG CANCER (ES-SCLC)
    Bilir, S. P.
    Ogale, S.
    VALUE IN HEALTH, 2020, 23 : S36 - S36
  • [10] Prognostic impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
    Ishihara, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S684 - S685
12345